Edwards Lifesciences Corporation (EW)

10 members of Congress have disclosed trading EW — 5 purchases and 11 sales worth an estimated $152,500. Most recent disclosure: Nov 19, 2025.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Company website ↗

• P/E ratio (49.1) — how many dollars you pay for each $1 of EW's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
• ROE (10.46%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
• Profit margin (17.39%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend — EW doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.